Latest News | Ireland Regulator Reports Manufacturing Deficiency at Biocon's Bengaluru Plant

New Delhi, May 3 (PTI) Biotechnology major Biocon Biologics on Tuesday said Ireland's health regulator has reported some deficiencies in the manufacturing process at the company's plant in Bengaluru.

The Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP (Good Manufacturing Practice) inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, between March 28 and April 1, 2022, a Biocon Biologics spokesperson said in a regulatory filing.

Also Read | Moto G82 Renders & Specifications Leaked Online: Report.

"The inspection report contains no 'critical' observations and only one of the deficiencies is categorised as 'major' which is being addressed expeditiously in consultation with the regulatory agency," the spokesperson added.

The facility will help the company address the additional requirements of products in the European Union market, the spokesperson noted.

Also Read | COVID-19 in Maharashtra: RT-PCR Test Made Mandatory for Patients Before Surgeries in Aurangabad.

Biocon Biologics is a subsidiary of Biocon Ltd.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)